Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.85 -0.7%	$2.72	$1.20 ▼ $6.37	$162.28M	2.87	1.93 million shs	416,249 shs
BTMD biote	$3.47 +3.3%	$3.80	$2.76 ▼ $6.98	$171.56M	1.21	173,084 shs	191,828 shs
KYTX Kyverna Therapeutics	$3.70 +0.3%	$3.50	$1.78 ▼ $8.28	$160.03M	3.05	367,107 shs	162,825 shs
SNTI Senti Biosciences	$1.55 -0.6%	$1.88	$1.46 ▼ $16.94	$40.55M	2.07	171,836 shs	125,774 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	-1.03%	+10.38%	-2.05%	+27.56%	-54.23%
BTMD biote	+1.51%	+13.13%	-23.11%	-6.67%	-44.37%
KYTX Kyverna Therapeutics	-2.38%	+7.58%	-14.78%	+40.30%	-54.16%
SNTI Senti Biosciences	-0.95%	-1.27%	-16.58%	-49.84%	-43.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.4093 of 5 stars	3.6	1.0	4.3	1.7	1.9
BTMD biote	2.6723 of 5 stars	3.3	2.0	2.8	1.7	1.3
KYTX Kyverna Therapeutics	2.5609 of 5 stars	3.6	2.0	2.7	1.7	0.6
SNTI Senti Biosciences	3.0453 of 5 stars	3.5	5.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.17	Buy	$12.40	332.81% Upside
BTMD biote	2.50	Moderate Buy	$6.00	67.60% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$15.60	314.89% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	448.39% Upside

Current Analyst Ratings Breakdown

Latest SNTI, BDTX, KYTX, and BTMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/11/2025	BDTX Black Diamond Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/8/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/7/2025	BTMD biote	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$8.00 ➝ $4.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
BTMD biote	$197.19M	0.90	$0.83 per share	4.32	($1.59) per share	-2.25
KYTX Kyverna Therapeutics	$7.03M	23.13	N/A	N/A	$4.26 per share	0.88
SNTI Senti Biosciences	$2.56M	15.84	N/A	N/A	$0.94 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	12.46	N/A	N/A	N/A	12.70%	9.58%	11/4/2025 (Estimated)
BTMD biote	$3.16M	$0.90	3.97	6.63	N/A	15.73%	-21.00%	18.26%	11/11/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	11/12/2025 (Estimated)
SNTI Senti Biosciences	-$52.79M	-$8.95	N/A	N/A	N/A	N/A	-223.98%	-76.02%	11/13/2025 (Estimated)

Latest SNTI, BDTX, KYTX, and BTMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A
8/7/2025	Q2 2025	SNTI Senti Biosciences	-$0.58	-$0.56	+$0.02	-$0.56	$1.30 million	$0.50 million
8/6/2025	Q2 2025	BTMD biote	$0.06	$0.10	+$0.04	$0.10	$49.52 million	$48.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BTMD biote	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
BTMD biote	N/A	0.98	0.74
KYTX Kyverna Therapeutics	N/A	5.39	5.39
SNTI Senti Biosciences	N/A	3.26	3.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BTMD biote	21.68%
KYTX Kyverna Therapeutics	18.08%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
BTMD biote	24.00%
KYTX Kyverna Therapeutics	22.00%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
BTMD biote	194	49.44 million	37.57 million	Not Optionable
KYTX Kyverna Therapeutics	96	43.25 million	33.73 million	Optionable
SNTI Senti Biosciences	4	26.16 million	25.34 million	Not Optionable

SNTI, BDTX, KYTX, and BTMD Headlines

Recent News About These Companies

Senti Biosciences (NASDAQ:SNTI) Upgraded to Hold at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

August 14, 2025 | globenewswire.com

Senti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor Segment

August 12, 2025 | quiverquant.comQ

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

August 12, 2025 | globenewswire.com

Senti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...

August 8, 2025 | finanznachrichten.de

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

August 7, 2025 | globenewswire.com

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

August 5, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/08/05/3127362/0/en/senti-bio-determines-recommended-phase-2-dose-rp2d-in-phase-1-study-of-senti-202-for-the-treatment-of-relapsed-refractory-hematologic-malignancies-including-acute-myeloid-leukemia.html$

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

July 21, 2025 | globenewswire.com

Senti Biosciences, Inc. Appoints Bryan Baum to Board of Directors

July 18, 2025 | quiverquant.comQ

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

July 18, 2025 | globenewswire.com

NASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.com

July 3, 2025 | investing.com

SNTI - Senti Biosciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Senti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight Series

June 30, 2025 | quiverquant.comQ

Senti Bio Participates in Nasdaq Amplify Spotlight Series

June 30, 2025 | globenewswire.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - Nasdaq

June 26, 2025 | nasdaq.com

Senti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies

June 24, 2025 | quiverquant.comQ

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

June 24, 2025 | globenewswire.com

Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation

June 18, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, BDTX, KYTX, and BTMD Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.85 -0.02 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.84 0.00 (-0.18%)

As of 05:30 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

biote NASDAQ:BTMD

$3.47 +0.11 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.60 +0.13 (+3.75%)

As of 04:53 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Kyverna Therapeutics NASDAQ:KYTX

$3.70 +0.01 (+0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.78 +0.07 (+2.03%)

As of 05:42 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Senti Biosciences NASDAQ:SNTI

$1.55 -0.01 (-0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.02 (+1.61%)

As of 05:21 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time